Redifferentiation therapy in unresectable or metastatic radioactive iodine refractory thyroid cancer: an International Thyroid Oncology Group statement
Open Access
- 1 May 2025
- journal article
- review article
- Published by Elsevier in The Lancet Diabetes & Endocrinology
- Vol. 13 (6) , 516-527
Abstract
No abstract availableKeywords
Funding Information
- National Institutes of Health
- Université de Genève
- National Cancer Institute (P30 CA008748)
This publication has 63 references indexed in Scilit:
- EANM expert opinion: How can lessons from radiobiology be applied to the design of clinical trials? Part I: back to the basics of absorbed dose–response and threshold absorbed dosesEuropean Journal of Nuclear Medicine and Molecular Imaging, 2024
- Successful radioiodine redifferentiation with selpercatinib in RET fusion-positive papillary thyroid carcinomaEuropean Journal of Nuclear Medicine and Molecular Imaging, 2024
- Genomic alterations in thyroid cancer: biological and clinical insightsNature Reviews Endocrinology, 2023
- Pathogenesis of cancers derived from thyroid follicular cellsNature Reviews Cancer, 2023
- ESMO Clinical Practice Guideline update on the use of systemic therapy in advanced thyroid cancerAnnals of Oncology, 2022
- I-124 PET/CT image-based dosimetry in patients with differentiated thyroid cancer treated with I-131: correlation of patient-specific lesional dosimetry to treatment responseAnnals of Nuclear Medicine, 2022
- Integrated Genomic Characterization of Papillary Thyroid CarcinomaCell, 2014
- Definition and management of radioactive iodine-refractory differentiated thyroid cancerThe Lancet Diabetes & Endocrinology, 2014
- Effectiveness of retinoic acid treatment for redifferentiation of thyroid cancer in relation to recovery of radioiodine uptakeJournal of Endocrinological Investigation, 2009
- Relation between Effective Radiation Dose and Outcome of Radioiodine Therapy for Thyroid CancerNew England Journal of Medicine, 1983